<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921098</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-05-01</org_study_id>
    <nct_id>NCT04921098</nct_id>
  </id_info>
  <brief_title>CPC in Adult Refractory Glaucoma</brief_title>
  <official_title>Evaluation of Diode Laser Cyclophotocoagulation in Adult Refractory Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relative effectiveness and safety of diode laser&#xD;
      cyclophotocoagulation procedure to reduce IOP and relieve pain in adult patients with&#xD;
      refractory glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A hospital -based, prospective interventional non comparative case series study.This study&#xD;
      will be conducted on patients with refractory glaucoma whose ages are 18 years and older.They&#xD;
      will be subjected to Transscleral Diode Laser Cyclophotocoagulation.&#xD;
&#xD;
      Postoperative evaluation will be scheduled for the first day postoperative, then 1 week later&#xD;
      and then at 1st, 3rd, month postoperative.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in intraocular pressure</measure>
    <time_frame>First day postoperative and 1 week</time_frame>
    <description>IOP measuring using Goldmann applanation tonometer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Refractory Glaucoma</condition>
  <arm_group>
    <arm_group_label>Refractory glaucoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diode Laser Cyclophotocoagulation</intervention_name>
    <description>A handpiece (G probe) is used to deliver the diode laser energy with a wavelength of 810 nm.</description>
    <arm_group_label>Refractory glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria:&#xD;
&#xD;
               1. Patients with refractory glaucoma aging 18 years and older.&#xD;
&#xD;
               2. Both sexes are included.&#xD;
&#xD;
               3. Patients Capable of giving informed consent.&#xD;
&#xD;
               4. Pseudophkic glaucoma.&#xD;
&#xD;
               5. Aphakic glaucoma.&#xD;
&#xD;
               6. Silicon oil induced glaucoma.&#xD;
&#xD;
               7. Neovascular glaucoma.&#xD;
&#xD;
               8. Inflammatory glaucoma.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients &lt;18 years of age.&#xD;
&#xD;
          2. Patients controlled on regular antiglaucomatous therapy.&#xD;
&#xD;
          3. Patients who cannot do regular follow up visits.&#xD;
&#xD;
          4. Diffuse scleral staphyloma at the site of CPC.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mina A Besada, Resident</last_name>
    <phone>01280899267</phone>
    <email>mena011205@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ismail M Abdellatif, Professor</last_name>
    <phone>01223629352</phone>
  </overall_contact_backup>
  <reference>
    <citation>Ansari E, Gandhewar J. Long-term efficacy and visual acuity following transscleral diode laser photocoagulation in cases of refractory and non-refractory glaucoma. Eye (Lond). 2007 Jul;21(7):936-40. Epub 2006 Apr 21.</citation>
    <PMID>16628239</PMID>
  </reference>
  <reference>
    <citation>Lai JS, Tham CC, Chan JC, Lam DS. Diode laser transscleral cyclophotocoagulation in the treatment of chronic angle-closure glaucoma: a preliminary study. J Glaucoma. 2003 Aug;12(4):360-4.</citation>
    <PMID>12897582</PMID>
  </reference>
  <reference>
    <citation>Nassiri N, Kamali G, Rahnavardi M, Mohammadi B, Nassiri S, Rahmani L, Nassiri N. Ahmed glaucoma valve and single-plate Molteno implants in treatment of refractory glaucoma: a comparative study. Am J Ophthalmol. 2010 Jun;149(6):893-902. doi: 10.1016/j.ajo.2010.01.025. Epub 2010 May 8.</citation>
    <PMID>20451896</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Mina Abdelmalek Besada</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

